Sept. 16, 2025 — Elutia Inc., a pioneer in drug-eluting biomatrix technologies, has published clinical and preclinical data supporting the clinical utility of a biologic envelope that secures cardiac implantable electronic devices (CIEDs), promotes tissue remodeling, and addresses bacterial colonization through localized antibiotic delivery. The data are published in the current issue of Frontiers in Cardiovascular Medicine.

Sept. 16, 2025 — Conavi Medical Corp., a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, announced it has submitted its next generation Novasight Hybrid IVUS/OCT intravascular imaging system to the U.S. Food and Drug Administration for 510(k) clearance for coronary applications.

Sept. 17, 2025 — Imperative Care recently announced positive efficacy and safety results from the pivotal Symphony-PE Trial (NCT06062329) evaluating the company’s Symphony Thrombectomy System in the treatment of acute pulmonary embolism (PE).

Sept. 8, 2025 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Microbot Medical's Liberty System, the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The FDA clearance positions the company to commercialize Liberty in the U.S., with the goal of transforming the field to enable accessibility to advanced robotics without the traditional constraints of capital equipment and a dedicated infrastructure.

Sept. 17, 2025 — Barbara Riegel, Ph.D., R.N., FAHA, Emerita Edith Clemmer Steinbright Professor of Gerontology at the University of Pennsylvania School of Nursing, will receive the American Heart Association’s 2025 Clinical Research Prize at the Association’s Scientific Sessions 2025. The meeting, taking place Nov. 7-10, 2025, in New Orleans is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. Dr. Riegel will be awarded during the Presidential Session on Sunday, Nov. 9, 2025.

Sept. 16, 2025 — PaceMate has appointed Sean Shoffstall as Head of AI, Innovation and Data Strategy. Shoffstall joins PaceMate after holding senior roles with Beginly Health, Welby Health and Auditdata, where he played an integral part in the launch of the first HIPAA-compliant AI-generated audiogram analysis tool in the industry.

Sept. 11, 2025 — Newswise —  A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women — are caused by factors other than clogged arteries, challenging long-standing assumptions about how heart attacks occur in younger populations.

Sept. 9, 2025 — Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, will present 30-day results of its POWER PAD II U.S. pivotal trial for Pulsatile Intravascular Lithotripsy (PIVL) therapy as a Late Breaking Clinical Trial (LBCT) at the Vascular InterVentional Advances (VIVA) meeting in November in Las Vegas.

Digital Tools Provide Insight into AFib

Atrial fibrillation (AFib) is one of the most common heart rhythm disorders, but researchers still don’t have a reliable way to predict who will develop it or when. Unlike conditions such as coronary disease, where biomarkers like high cholesterol provide early warning signs and treatment options, AFib lacks a definitive predictor.

Sept. 2, 2025 — Although cardiovascular disease is a leading cause of death for women, they remain underrepresented in clinical trials for common heart conditions. These findings, by investigators in the Smidt Heart Institute at Cedars-Sinai, were presented at the 2025 European Society of Cardiology Congress in Madrid.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now